On October 20, 2023, the first-in-human trial of BDC-1001 in advanced HER2-positive solid tumors was reported at the ESMO Congress.

REGENXBIO Inc. reveals positive additional results from ongoing Phase II ALTITUDE® study. The study pertains to ABBV-RGX-314, expected for treating diabetic retinopathy except center-involved diabetic macular edema, and is given through in-office suprachoroidal delivery.

AKT (Protein Kinase B), a pivotal player in PI3K/AKT/m-TOR signaling pathway, is a prospective drug target clinically. Its activation is crucial for cell survival and growth, implicating in tumorigenesis and metastasis. Research indicates AKT over-activation in over 50% of tumors.

This article summarized the latest R&D progress of Norelgestromin, the Mechanism of Action for Norelgestromin, and the drug target R&D trends for Norelgestromin.

Ankyra Therapeutics has published encouraging preclinical results for the combined use of ANK-101, a new anchored immune therapy, and cytotoxic chemotherapy in a head and neck cancer model.

The Fab fragment, also known as the antigen-binding fragment, is the region of an antibody that can bind with antigens.

Scholar Rock shares fresh results from its phase 1 DRAGON trial, indicating anti-tumor potential in patients with metastatic ccRCC who are resistant to Anti-PD-1. The data also backs the ongoing tolerability of SRK-181.

This article summarized the latest R&D progress of Oxiconazole Nitrate, the Mechanism of Action for Oxiconazole Nitrate, and the drug target R&D trends for Oxiconazole Nitrate.

Acetylcholinesterase (AChE), the primary cholinesterase in the body, is an enzyme catalyzing the breakdown of acetylcholine and of some other choline esters that function as neurotransmitters.

Cue Biopharma shares encouraging results from Phase 1 studies for CUE-101 for Head and Neck Cancer, and CUE-102 for Wilms' Tumor 1 related cases, at the SITC 2023 event.

A Polyclonal antibody (PAb) is a mixture of antibodies produced by different B cells in the body against the same antigen.

At the 38th Society for Immunotherapy of Cancer Meeting, Adagene Inc. presented new data on its anti-CTLA-4 SAFEbody ADG126, revolutionizing new antibody-related therapies.